COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000931976
Ethics application status
Yes
Date submitted
19/08/2011
Date registered
30/08/2011
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
Telmisartan in the management of abdominal aortic aneurysm
Scientific title
The effects of Telmisartan, an angiotensinII type 1 receptor blocker, in reducing AAA growth in patients with abdominal aortic aneurysm.
Secondary ID [1] 262875 0
Nil
Universal Trial Number (UTN)
U1111-1119-8488
Trial acronym
TEDY
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Abdominal Aortic Aneurysm 261285 0
Condition category
Condition code
Cardiovascular 259433 259433 0 0
Coronary heart disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Angiotensin II type 1 receptor blocker, oral tablet, 40mg daily for 12 months.
Intervention code [1] 264137 0
Treatment: drugs
Comparator / control treatment
Placebo, sugar pill that is identical in appearance to Telmisartan but without the active ingredient.
Control group
Placebo

Outcomes
Primary outcome [1] 262240 0
Reduced AAA growth found by CT measure.
Timepoint [1] 262240 0
CT conducted every 12 months for a period of up to 5 years.
Primary outcome [2] 279510 0
Reduced AAA growth found by US measure.
Timepoint [2] 279510 0
US measured at baseline, every 6 months and at 12 months, for a duration of up to 5 years.
Secondary outcome [1] 273371 0
Ambulatory blood pressure
Timepoint [1] 273371 0
Ambulatory blood pressure measured at baseline and at 12 months, for a period of up to 5 years.
Secondary outcome [2] 287770 0
SF36 quality of life questionnaire.
Timepoint [2] 287770 0
Quality of life measured at baseline and at 12 months, for a period of up to 5 years.
Secondary outcome [3] 287771 0
Blood biomarkers (SST tubes x 2, EDTA tubes x 2, Citrate tube x 1, PaxGene tube x 1).
Timepoint [3] 287771 0
Blood biomarkers measured at entry, every 6 months and at 12 months, for a period of up to 5 years.

Eligibility
Key inclusion criteria
1. Written informed consent
2. AAA measuring a maximum diameter of 35-49 mm on CTA;
3. No current indication for AAA repair according to the treating physician or expectation that this will be revised within the next year;
4. High likelihood of compliance with treatment over 12 months;
5. No contraindications to study treatment, including: renal impairment (i.e. creatinine >1.5x upper limit of normal [ULN]), known significant renal stenosis (>70%) of one or both renal arteries, chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e. ALT 1.5xULN), electrolyte imbalance and gout;
6. No current or planned usage of an AT1 blocker or ACE inhibitors.
Minimum age
40 Years
Maximum age
85 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Contraindications to study treatment
2. Non-compliant to treatment/testing
3. Current usage of an AT1 blocker or ACE inhibitor.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation stratified by aortic size and study site
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Strateified randomisation using a computer software program (computerized sequence generation).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Nil
Phase
Phase 2
Type of endpoint(s)
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 281721 0
State/province [1] 281721 0
Country [2] 281722 0
State/province [2] 281722 0
Country [3] 281723 0
State/province [3] 281723 0
Country [4] 281724 0
State/province [4] 281724 0
Country [5] 281725 0
State/province [5] 281725 0
Country [6] 281726 0
State/province [6] 281726 0

Funding & Sponsors
Funding source category [1] 269698 0
Other
Name [1] 269698 0
BUPA
Address [1] 269698 0
Bupa Australia
600 Glenferrie Rd
Hawthorn
Victoria
3122
Country [1] 269698 0
Australia
Primary sponsor type
University
Name
James Cook University
Address
James Cook Drive
Douglas, Townsville
Queensland 4811
Country
Australia
Secondary sponsor category [1] 268734 0
None
Name [1] 268734 0
Address [1] 268734 0
Country [1] 268734 0
Other collaborator category [1] 252211 0
Hospital
Name [1] 252211 0
Townsville Hospital
Address [1] 252211 0
100 Angus Smith Dr,
Douglas QLD 4814
Country [1] 252211 0
Australia
Other collaborator category [2] 252212 0
Hospital
Name [2] 252212 0
Mater Health Services NQ Ltd
Address [2] 252212 0
21-37 Fulham Rd,
Pimlico
Queensland QLD 4812
Country [2] 252212 0
Australia
Other collaborator category [3] 252213 0
Hospital
Name [3] 252213 0
Royal Brisbane Women's Hospital
Address [3] 252213 0
Cnr Butterfield and Bowen Bridge Rd
Brisbane
Queensland 4029
Country [3] 252213 0
Australia
Other collaborator category [4] 252214 0
Hospital
Name [4] 252214 0
Fremantle Hospital
Address [4] 252214 0
Alma St,
Fremantle
Western Australia 6959
Country [4] 252214 0
Australia
Other collaborator category [5] 252215 0
Hospital
Name [5] 252215 0
Alfred Hospital
Address [5] 252215 0
Commercial Road
Prahran
Victoria 3181
Country [5] 252215 0
Australia

Ethics approval
Ethics application status
Yes
Ethics committee name [1] 271656 0
Townsville Health Service District
Ethics committee address [1] 271656 0
100 Angus Smith Dr
Douglas QLD 4814
Ethics committee country [1] 271656 0
Australia
Date submitted for ethics approval [1] 271656 0
08/01/2010
Approval date [1] 271656 0
12/04/2010
Ethics approval number [1] 271656 0
HREC/09/QTHS/117
Ethics committee name [2] 271657 0
JCU Human Research Ethics Committee
Ethics committee address [2] 271657 0
Douglas, Townsville
QLD 4811
Ethics committee country [2] 271657 0
Australia
Date submitted for ethics approval [2] 271657 0
Approval date [2] 271657 0
12/04/2010
Ethics approval number [2] 271657 0
C7
Ethics committee name [3] 271658 0
Mater Health Services NQ Ltd
Ethics committee address [3] 271658 0
21-37 Fulham Rd
Pimlico, Townsville
QLD 4812
Ethics committee country [3] 271658 0
Australia
Date submitted for ethics approval [3] 271658 0
Approval date [3] 271658 0
21/09/2010
Ethics approval number [3] 271658 0
EC00412
Ethics committee name [4] 271659 0
Alfred Hospital Ethics Committee
Ethics committee address [4] 271659 0
Commercial Road,
Melbourne
VIC 3181
Ethics committee country [4] 271659 0
Australia
Date submitted for ethics approval [4] 271659 0
25/02/2010
Approval date [4] 271659 0
20/05/2010
Ethics approval number [4] 271659 0
23/10/2011
Ethics committee name [5] 271660 0
Royal Brisbane and Women's Hospital Metro North Health Service District
Ethics committee address [5] 271660 0
Cnr Butterfield & Bowen Bridge Rd
Herston
QLD 4029
Ethics committee country [5] 271660 0
Australia
Date submitted for ethics approval [5] 271660 0
08/01/2010
Approval date [5] 271660 0
23/06/2010
Ethics approval number [5] 271660 0
HREC/10/WRBW/28
Ethics committee name [6] 271661 0
Government of Western Australia Department of Health South Metropolitan Area Health Service
Ethics committee address [6] 271661 0
Alma St
Fremantle
WA 6959
Ethics committee country [6] 271661 0
Australia
Date submitted for ethics approval [6] 271661 0
10/08/2010
Approval date [6] 271661 0
24/08/2010
Ethics approval number [6] 271661 0
1/10/0317

Summary
Brief summary
The primary purpose of the study is to investigate telmisartan as a novel therapy for patients with abdominal aortic aneurysms. We hypothesize that telmisartan will reduce AAA growth.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Contact person for public queries
Contact person for scientific queries

No information has been provided regarding IPD availability
Summary results
No Results